Pusy, you`re so wrong. Last year was another situation; now they have a new business driven CEO (look up his CV... !), stronger IP-value and new patents (they are very protective with this important factor) - and foremost; products to sell and they are all more experienced in the team/company.


Another thing; this is such a new business - if you invest (the big boys on Wall Street), you want to have the right "credentials" of the management and advisory board. This business is the top notch in cannabis pharma knowledge, many years of study the subject.


Sure, we all get down now and then... but this time (from now and coming months ahead) we will surely make a very good ROI. Hang in there !